139 related articles for article (PubMed ID: 37531744)
1. RIPK2 inhibitors for disease therapy: Current status and perspectives.
Tian E; Zhou C; Quan S; Su C; Zhang G; Yu Q; Li J; Zhang J
Eur J Med Chem; 2023 Nov; 259():115683. PubMed ID: 37531744
[TBL] [Abstract][Full Text] [Related]
2. Design of pyrido[2,3-d]pyrimidin-7-one inhibitors of receptor interacting protein kinase-2 (RIPK2) and nucleotide-binding oligomerization domain (NOD) cell signaling.
Nikhar S; Siokas I; Schlicher L; Lee S; Gyrd-Hansen M; Degterev A; Cuny GD
Eur J Med Chem; 2021 Apr; 215():113252. PubMed ID: 33601309
[TBL] [Abstract][Full Text] [Related]
3. Inflammatory Signaling by NOD-RIPK2 Is Inhibited by Clinically Relevant Type II Kinase Inhibitors.
Canning P; Ruan Q; Schwerd T; Hrdinka M; Maki JL; Saleh D; Suebsuwong C; Ray S; Brennan PE; Cuny GD; Uhlig HH; Gyrd-Hansen M; Degterev A; Bullock AN
Chem Biol; 2015 Sep; 22(9):1174-84. PubMed ID: 26320862
[TBL] [Abstract][Full Text] [Related]
4. Small molecule inhibitors reveal an indispensable scaffolding role of RIPK2 in NOD2 signaling.
Hrdinka M; Schlicher L; Dai B; Pinkas DM; Bufton JC; Picaud S; Ward JA; Rogers C; Suebsuwong C; Nikhar S; Cuny GD; Huber KV; Filippakopoulos P; Bullock AN; Degterev A; Gyrd-Hansen M
EMBO J; 2018 Sep; 37(17):. PubMed ID: 30026309
[TBL] [Abstract][Full Text] [Related]
5. In vivo inhibition of RIPK2 kinase alleviates inflammatory disease.
Tigno-Aranjuez JT; Benderitter P; Rombouts F; Deroose F; Bai X; Mattioli B; Cominelli F; Pizarro TT; Hoflack J; Abbott DW
J Biol Chem; 2014 Oct; 289(43):29651-64. PubMed ID: 25213858
[TBL] [Abstract][Full Text] [Related]
6. Receptor-interacting protein kinase 2 (RIPK2) and nucleotide-binding oligomerization domain (NOD) cell signaling inhibitors based on a 3,5-diphenyl-2-aminopyridine scaffold.
Suebsuwong C; Dai B; Pinkas DM; Duddupudi AL; Li L; Bufton JC; Schlicher L; Gyrd-Hansen M; Hu M; Bullock AN; Degterev A; Cuny GD
Eur J Med Chem; 2020 Aug; 200():112417. PubMed ID: 32505849
[TBL] [Abstract][Full Text] [Related]
7. Design, synthesis and evaluation of novel thieno[2,3d]pyrimidine derivatives as potent and specific RIPK2 inhibitors.
Misehe M; Šála M; Matoušová M; Hercík K; Kocek H; Chalupská D; Chaloupecká E; Hájek M; Boura E; Mertlíková-Kaiserová H; Nencka R
Bioorg Med Chem Lett; 2024 Jan; 97():129567. PubMed ID: 38008339
[TBL] [Abstract][Full Text] [Related]
8. RIPK2 as a promising druggable target for autoimmune diseases.
Zhao W; Leng RX; Ye DQ
Int Immunopharmacol; 2023 May; 118():110128. PubMed ID: 37023697
[TBL] [Abstract][Full Text] [Related]
9. Discovery of Potent and Selective Receptor-Interacting Serine/Threonine Protein Kinase 2 (RIPK2) Inhibitors for the Treatment of Inflammatory Bowel Diseases (IBDs).
Yuan X; Chen Y; Tang M; Wei Y; Shi M; Yang Y; Zhou Y; Yang T; Liu J; Liu K; Deng D; Zhang C; Chen L
J Med Chem; 2022 Jul; 65(13):9312-9327. PubMed ID: 35709396
[TBL] [Abstract][Full Text] [Related]
10. Recent advances in the development of RIPK2 modulators for the treatment of inflammatory diseases.
Pham AT; Ghilardi AF; Sun L
Front Pharmacol; 2023; 14():1127722. PubMed ID: 36959850
[TBL] [Abstract][Full Text] [Related]
11. RIPK2 Dictates Insulin Responses to Tyrosine Kinase Inhibitors in Obese Male Mice.
Duggan BM; Cavallari JF; Foley KP; Barra NG; Schertzer JD
Endocrinology; 2020 Aug; 161(8):. PubMed ID: 32473019
[TBL] [Abstract][Full Text] [Related]
12. Assaying RIPK2 Activation by Complex Formation.
Steinle H; Ellwanger K; Kufer TA
Methods Mol Biol; 2022; 2523():133-150. PubMed ID: 35759195
[TBL] [Abstract][Full Text] [Related]
13. A RIPK2 inhibitor delays NOD signalling events yet prevents inflammatory cytokine production.
Nachbur U; Stafford CA; Bankovacki A; Zhan Y; Lindqvist LM; Fiil BK; Khakham Y; Ko HJ; Sandow JJ; Falk H; Holien JK; Chau D; Hildebrand J; Vince JE; Sharp PP; Webb AI; Jackman KA; Mühlen S; Kennedy CL; Lowes KN; Murphy JM; Gyrd-Hansen M; Parker MW; Hartland EL; Lew AM; Huang DC; Lessene G; Silke J
Nat Commun; 2015 Mar; 6():6442. PubMed ID: 25778803
[TBL] [Abstract][Full Text] [Related]
14. RIPK2: a promising target for cancer treatment.
You J; Wang Y; Chen H; Jin F
Front Pharmacol; 2023; 14():1192970. PubMed ID: 37324457
[TBL] [Abstract][Full Text] [Related]
15. Receptor-interacting protein kinase 2 contributes to host innate immune responses against Fusobacterium nucleatum in macrophages and decidual stromal cells.
Park JY; Lee TS; Noh EJ; Jang AR; Ahn JH; Kim DY; Jung DH; Song EJ; Lee YJ; Lee YJ; Lee SK; Park JH
Am J Reprod Immunol; 2021 Jul; 86(1):e13403. PubMed ID: 33580557
[TBL] [Abstract][Full Text] [Related]
16. The potent and selective RIPK2 inhibitor BI 706039 improves intestinal inflammation in the TRUC mouse model of inflammatory bowel disease.
Ermann J; Matmusaev M; Haley EK; Braun C; Jost F; Mayer-Wrangowski S; Hsiao P; Ting N; Li L; Terenzio D; Chime J; Lukas S; Patnaude L; Panzenbeck M; Csordas D; Zheng J; Mierz D; Simpson T; King FJ; Klimowicz AP; Mbow ML; Fine JS; Miller CA; Fogal SE; Byrne FR
Am J Physiol Gastrointest Liver Physiol; 2021 Nov; 321(5):G500-G512. PubMed ID: 34494462
[TBL] [Abstract][Full Text] [Related]
17. Identification and Characterization of Novel Receptor-Interacting Serine/Threonine-Protein Kinase 2 Inhibitors Using Structural Similarity Analysis.
Salla M; Aguayo-Ortiz R; Danmaliki GI; Zare A; Said A; Moore J; Pandya V; Manaloor R; Fong S; Blankstein AR; Gibson SB; Garcia LR; Meier P; Bhullar KS; Hubbard BP; Fiteh Y; Vliagoftis H; Goping IS; Brocks D; Hwang P; Velázquez-Martínez CA; Baksh S
J Pharmacol Exp Ther; 2018 May; 365(2):354-367. PubMed ID: 29555876
[TBL] [Abstract][Full Text] [Related]
18. A regulatory region on RIPK2 is required for XIAP binding and NOD signaling activity.
Heim VJ; Dagley LF; Stafford CA; Hansen FM; Clayer E; Bankovacki A; Webb AI; Lucet IS; Silke J; Nachbur U
EMBO Rep; 2020 Nov; 21(11):e50400. PubMed ID: 32954645
[TBL] [Abstract][Full Text] [Related]
19. Identification of Novel Protein Kinase Receptor Type 2 Inhibitors Using Pharmacophore and Structure-Based Virtual Screening.
Cruz JV; Neto MFA; Silva LB; da S Ramos R; da S Costa J; Brasil DSB; Lobato CC; da Costa GV; Bittencourt JAHM; da Silva CHTP; Leite FHA; Santos CBR
Molecules; 2018 Feb; 23(2):. PubMed ID: 29463017
[TBL] [Abstract][Full Text] [Related]
20. 14-3-3 and erlin proteins differentially interact with RIPK2 complexes.
Steinle H; Ellwanger K; Mirza N; Briese S; Kienes I; Pfannstiel J; Kufer TA
J Cell Sci; 2021 Jun; 134(12):. PubMed ID: 34152391
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
